冠心病患者行非心脏手术围术期抗血小板治疗管理策略  

Perioperative management of antiplatelet therapy in patients with coronary artery disease undergoing non-cardiac surgery

作　　者：白瑾[1] 张永珍[1] Bai Jin;Zhang Yongzhen(Department of Cardiology,Third Hospital of Peking University,Beijing 100191,China)

机构地区：[1]北京大学第三医院心血管内科,北京100191

出　　处：《中华老年多器官疾病杂志》2023年第10期787-790,共4页Chinese Journal of Multiple Organ Diseases in the Elderly

基　　金：北京慢性病防治与健康教育研究会科研项目(BJMB0012022028003)。

摘　　要：抗血小板治疗是冠心病二级预防的基石,但有增加出血的潜在风险,围术期抗血小板治疗决策务必要权衡个体血栓与出血风险和推迟非心脏手术潜在后果之间的平衡。围术期抗血小板治疗的管理应个体化,由多学科小组和患者共同决策,将血栓风险和出血风险降至最低。目前指南提供的建议并不一致,优化管理策略仍未确定。Antiplatelet therapy is the cornerstone of secondary prevention of coronary artery disease but potentially increases the risk of bleeding.A process of shared decision-making for perioperative antiplatelet therapy must balance an individual′s thrombotic and bleeding risk,and the potential unintended consequences of delaying non-cardiac surgery.Perioperative management of antiplatelet therapy should be individually tailored based on consensus from multidisciplinary team and patient to minimize both thrombotic and bleeding risks.Current guidelines do not provide consistent recommendations on this topic,and the optimal approach in these patients is yet to be determined.

关 键 词：冠心病 非心脏手术 抗血小板治疗 出血 主要不良心血管事件 

分 类 号：R541[医药卫生—心血管疾病]